Posted on March 6, 2011 by Sitemaster
A while back now the research group at M. D. Anderson Cancer Center initiated a Phase II clinical trial of a drug called tandutinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already had taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, mCRPC, PDGF, PDGFR, platelet-derived growth factor, receptor, tandutinib | Leave a comment »
Posted on November 28, 2008 by Sitemaster
In today’s news reports, among other items, we cover:
- Risk for prostate cancer 4 years after initial screening
- Presumptive antibiotic therapy for an elevated PSA level
- The morphology of cancer cell nuclei in men with Gleason 7 disease
- MRI in prostate cancer diagnosis and staging
- PDGFR levels and the efficacy of docetaxel (Taxotere) … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: antibiotic, elevated PSA, morphology, MRI docetaxelo, nucleus, PDGFR, risk | Leave a comment »
